Close

Industry Reports

Pivotal Therapeutics reports third quarter 2012 financial results

Pivotal Therapeutics Inc. , a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar...

Hybrigenics 2012 first-half results

Plus 5 per cent growth of Hybrigenics’ operating revenues An exceptional revenue of EUR 0.96 million EUR 3.3 million raised to finance the clinical study of oral inecalcitol in chronic lymphocytic leukemia Paris, October...

Johnson & Johnson Reports 2012 Third-Quarter Results

Sales of $17.1 Billion increased 6.5% Versus 2011 Third Quarter; Third-Quarter EPS was $1.05 Excluding Special Items, 2012 Third-Quarter EPS of $1.25 increased 0.8%* Johnson & Johnson today announced sales of $17.1 billion for...

Roche Group posts strong sales growth in the third quarter

Roche sales grew 4% to 33.7 billion Swiss francs thanks to strong demand for its cancer medicines and its clinical lab business. Uptake of the Group's recently launched cancer medicines Zelboraf, Erivedge and Perjeta has been positive. The...

BIOGEN IDEC TO REPORT THIRD QUARTER 2012 FINANCIAL RESULTS ON OCTOBER 25, 2012

Biogen Idec Inc. today announced it will report third quarter 2012 financial results on Thursday, October 25, 2012, before the financial markets open. Following the release of the financials, the Company will host a live webcast...

Interleukin Genetics Reports Second Quarter 2012 Financial Results

Interleukin Genetics, Inc. today announced financial and operational results for the second quarter ended June 30, 2012. Total revenue for the three months ended June 30, 2012 was $799,000, compared to $797,000 for the...

Sanofi second-quarter and first-half sales 2012

In the second quarter of 2012, Sanofi generated net sales of €8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read